Navigation Links
TAXUS(R) Liberte(R) Stent Continues to Demonstrate Significant Improvements Over TAXUS(R) Express(R) Stent in Small Vessels and Long Lesions
Date:9/22/2009

rombosis (p=0.49) using the Protocol definition and 3.9 percent (p=0.03) using the ARC definition.

"The TAXUS ATLAS studies continue to show that the TAXUS Liberte Stent delivers significant improvements over the TAXUS Express Stent in small vessels and long lesions," said Hank Kucheman, Senior Vice President and Group President, Cardiovascular for Boston Scientific. "TAXUS Stents have been evaluated by the industry's most extensive clinical trial program and the next-generation TAXUS Liberte Stent is the only platform to offer both 2.25 mm and 38 mm drug-eluting stents. TAXUS Liberte continues to be an effective treatment option for coronary artery disease that has earned the confidence of physicians worldwide."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings, product performance and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results coul
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Boston Scientific PROMUS(R) and First-Generation TAXUS(R) Express(R) Stents Continue Excellent Performance in SPIRIT III Trial
2. FDA Approves Boston Scientifics TAXUS(R) Liberte(R) Long Stent
3. SYNTAX Substudy Shows Positive Outcomes for Left Main Patients Treated With TAXUS(R) Express2(R) Stent System
4. Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System
5. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients with Diabetes Compared to Non-Diabetics in ARRIVE Registry Program
6. TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients
7. A consistent decline in heart attack rates following the implementation of smoking bans
8. Drug-eluting stents safe, effective for treatment of chronic total occlusions
9. Researchers find drug-eluting stents safe, effective for PCI in diabetics
10. New type of sirolimus-eluting stent demonstrates superior results
11. Sono-Tek Announces its Largest Ever Sales of MediCoat Stent Coating Systems to a Leading Global Medical Device Manufacturer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... 2014 Cooking and warming equipment ... of 5. This score reflects slightly positive negotiation conditions ... specialization, low switching costs and a low level of ... low availability of substitutes for cooking and warming equipment ... and aluminum, key inputs in the production process of ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 Plugin and template ... TransPack Volume 5 Plugin for Final Cut Pro X. , ... hard light tool to pull off an industry professional look” ... get their hands on TransPack Volume 5, a new level ... is a set of over 50 Final Cut Pro X ...
(Date:12/26/2014)... 26, 2014 Pentec Health, Inc. number ... state of Pennsylvania for 2014. The awards program, created ... of its kind in the country. The program is ... Department of Community and Economic Development, the Pennsylvania State ... the Central Penn Business Journal. , Charlie ...
(Date:12/25/2014)... The microscopy market is estimated to grow at ... by 2019. Optical microscopy is the largest segment ... segment is expected to show the fastest growth ... nanotechnology, technological advancements, and increasing federal support to ... Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... and Market Analysis to 2023” focuses on the ... commercial opportunities in the colorectal cancer market. Stivarga ... treatment of colon or rectal cancer. Boehringer Ingelheim ... inhibitor, for the treatment of refractory CRC in ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... suffer an adverse medical event arising from the use or ... system than other emergency department (ED) patients, say physicians and ... the first to examine the health outcomes and cost of ... drug events, is published today in the Annals of ...
... By Amanda Gardner HealthDay Reporter , THURSDAY, ... of plague will probably remain a scourge of centuries past, ... In fact, according to a just-released government report, a American ... case of plague from a laboratory-acquired infection since 1959 and ...
... in one large U.S. healthcare network since publication of ... according to a study published online February 24 in ... In 2008, the U.S. Preventive Services Task Force ... The following year, investigators from two large screening trials ...
... experiences and substance abuse has been discovered by researchers ... correlation is especially prevalent among gays, lesbians and bisexuals ... professor and interim head of health systems science in ... of the study, published in the journal Addiction ...
... , THURSDAY, Feb. 24 (HealthDay News) -- Fewer ... antigen (PSA) screening for prostate cancer since the release of ... a few years ago, say researchers. This study examined ... the decline in PSA screening was three percent among men ...
... been associated with a reduced risk of breast cancer, but ... gives birth, the higher her risk of "triple-negative" breast cancer, ... Conversely, women who never give birth have a 40 percent ... prognosis than other types of breast cancer and doesn,t respond ...
Cached Medicine News:Health News:Adverse drug events costly to health care system: Vancouver Coastal Health-UBC research 2Health News:Plague Kills U.S. Lab Worker 2Health News:Plague Kills U.S. Lab Worker 3Health News:Strong link found between victimization, substance abuse 2Health News:PSA Screening for Prostate Cancer Dips in Large U.S. Health Network 2Health News:Multiple childbirth linked to increased risk of rare, aggressive 'triple-negative' breast cancer 2Health News:Multiple childbirth linked to increased risk of rare, aggressive 'triple-negative' breast cancer 3
(Date:12/24/2014)... 2014   Synageva BioPharma Corp. (NASDAQ: ... therapeutic products for rare disorders, today announced validation ... Marketing Authorization Application (MAA) for sebelipase alfa for ... request for accelerated assessment, which has the potential ... The MAA, and the Biologics License ...
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
(Date:12/22/2014)... JUNCTION, N.J. , Dec. 22, 2014 /PRNewswire/ ... company marketing its CytoSorb® blood purification technology to ... surgery patients in 28 countries worldwide, today announced ... Russo , MD, FACS, as its Senior Vice ... Dr. Di Russo ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... Omnicell, Inc. (Nasdaq: OMCL ) a leading ... they will present at the UBS 21st Annual Global Healthcare ... Omnicell Speakers: Rob Seim, vice president ... DevelopmentDate: Tuesday, February 8, 2011Time: 11:00 a.m. ESTLocation: ...
... LLC , ( www.curemark.com ), a drug research and ... recently hosted New York Senator Kirsten Gillibrand as she ... creation, locally and nationally.  Speaking at Curemark, which is ... proposal to expand, simplify and make permanent the Research ...
Cached Medicine Technology:Omnicell to Present at the UBS 21st Annual Global Healthcare Services Conference 2Curemark Hosts New York Senator Kirsten Gillibrand 2Curemark Hosts New York Senator Kirsten Gillibrand 3
... The Burdick EK-10 single-channel,electrocardiograph ... touch membrane keypad. It ... make a quick and,accurate ... ergonomically,designed with a built ...
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
... CSV-1000LanC 10% test face is ... uses the Landolt C in ... targets. The targets are presented ... is very useful for evaluating ...
... is used to evaluate both low contrast acuity ... and 12.5%) of LogMAR acuity (20/16 to 20/100) ... as the two spatial frequencies of 6 and ... for cataract documentation because eye doctors can document ...
Medicine Products: